1 not yet recruiting, 1 recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Apixaban 2.5 mg twice daily: new trials by email Literature Review of Apixaban 2.5 mg twice daily trials Research Report on Apixaban 2.5 mg twice daily
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Apixaban to Prevent Decompensation of Early Liver Cirrhosis Trial Apixaban 2.5 mg twice daily, Placebo - Liver Cirrhosis | Phase 3 | Not yet recruiting | University College, London | 1142 | 2026-07-15 | 2026-07-24 |
| DOAC - Dosing Options in AntiCoagulation Prophylaxis Apixaban 2.5 mg twice daily, Apixaban 5 mg once daily, No anticoagulation - Cancer, VTE (Venous Thromboembolism) | Phase 3 | Recruiting | University of Vermont | 996 | 2025-10-17 | 2026-02-05 |
Liver Cirrhosis (1) · Neoplasms (1) · Venous Thromboembolism (1)
University College, London (1) · University of Vermont (1)
United States (1)
Alastair O'Brien (1)